Abstract-The low prevalence of coronary heart disease in premenopausal women and its increase after menopause are well established. Although estrogen is thought to play a role in protecting the vasculature, the mechanism has not been fully clarified. The contribution of platelets to atherosclerotic cardiovascular diseases is well recognized. The present study focused on the still-controversial effect of estrogen on platelet function. We investigated the in vitro effects of estrogen on human platelets, including their aggregation, Ca 2ϩ metabolism, the synthesis of cyclic nucleotides, and NO (nitrite/nitrate) synthesis after stimulation with thrombin or ADP. Pretreatment of platelets with 17␤-estradiol reduced the platelet aggregation induced by thrombin or ADP, whereas 17␣-estradiol had no effect. 17␤-Estradiol accelerated the recovery of [Ca 2ϩ ] i after the agonist-induced peak and reduced the area under the curve of accumulated platelet [Ca 2ϩ ] i but did not alter the baseline [Ca 2ϩ ] i , Ca 2ϩ influx induced by thrombin or ADP, the release of Ca 2ϩ from internal stores, or the size of internal Ca 2ϩ stores. Pretreatment of platelets with 17␤-estradiol had no effect on the intracellular concentration of cAMP but increased that of cGMP in agonist-stimulated platelets. Additionally, 17␤-estradiol increased the platelet concentration of nitrite/nitrate in a dose-dependent manner. These effects of 17␤-estradiol on platelet aggregation, Ca 2ϩ metabolism, and NO synthesis were abolished by exposure to N G -monomethyl-L-arginine, an NO synthesis inhibitor. These results suggest that 17␤-estradiol plays an important role in inhibiting platelet aggregation by promoting Ca 2ϩ extrusion or reuptake activity that is dependent on the production of cGMP by increasing NO synthesis. 1 Estrogen replacement therapy has been shown to reduce the risk of coronary atherosclerosis in postmenopausal women.
] i after the agonist-induced peak and reduced the area under the curve of accumulated platelet [Ca 2ϩ ] i but did not alter the baseline [Ca 2ϩ ] i , Ca 2ϩ influx induced by thrombin or ADP, the release of Ca 2ϩ from internal stores, or the size of internal Ca 2ϩ stores. Pretreatment of platelets with 17␤-estradiol had no effect on the intracellular concentration of cAMP but increased that of cGMP in agonist-stimulated platelets. Additionally, 17␤-estradiol increased the platelet concentration of nitrite/nitrate in a dose-dependent manner. These effects of 17␤-estradiol on platelet aggregation, Ca 2ϩ metabolism, and NO synthesis were abolished by exposure to N G -monomethyl-L-arginine, an NO synthesis inhibitor. These results suggest that 17␤-estradiol plays an important role in inhibiting platelet aggregation by promoting Ca 2ϩ extrusion or reuptake activity that is dependent on the production of cGMP by increasing NO synthesis. (Arterioscler Thromb Vasc Biol. 1998;18:961-967.) Key Words: 17␤-estradiol Ⅲ platelet aggregation Ⅲ c GMP Ⅲ nitric oxide Ⅲ intracellular Ca 2ϩ E strogen is important in preventing atherosclerotic vascular diseases. For example, after menopause, women become as vulnerable to death due to cardiovascular disease as are men. 1 Estrogen replacement therapy has been shown to reduce the risk of coronary atherosclerosis in postmenopausal women. [2] [3] [4] Several mechanisms are postulated for this antiatherosclerotic effect; among them are the improvement of the lipid profile 5, 6 and a direct vasodilator effect of estrogen. 7 Concerning the latter, in vitro studies have reported that human endothelial NO synthesis can be regulated by estrogen 8)-10 and that estrogen can inhibit the contraction of coronary smooth muscle mainly by the inhibition of Ca 2ϩ influx 11 . Paradoxically, epidemiological investigations have shown that women who take oral contraceptives are at an increased risk for thromboembolic events, such as deep-vein thrombosis of the lower limbs or pulmonary embolism. 12 , 13 The aggregating and secreting responses of platelets are intimately involved in the development of atherosclerotic plaque and the thromboembolic complications that result from plaque rupture. 14, 15 However, the effect of estrogen on platelet function remains controversial. 16 -22 Accordingly, the main purposes of the present study were to examine the effects of estrogen on platelet function and to clarify mechanism of the phenomenon. We investigated the effects of estrogen on the aggregation of human platelets stimulated in vitro by thrombin, a strong agonist, or by ADP, a weak physiological agonist. We also attempted to determine the effects of estrogen on the metabolism of such intracellular second messengers as Ca 2ϩ and cyclic nucleotides in platelets. We analyzed the concentration of NO and the effects of inhibition of NO synthesis by N G -monomethyl-L-arginine (L-NMMA) on platelets pretreated with estrogen to determine whether this phenomenon could be related to NO synthesis, in that estrogen intimately linked to NO synthesis in several other cell types and intrinsic NO synthesis have been demonstrated in human platelets.
Methods

Materials
The ovarian steroids 17␣-estradiol and 17␤-estradiol (Sigma Chemical Co) were dissolved in 95% ethanol and diluted 100-fold to obtain a final concentration of 0.95% each. This concentration of ethanol was determined to have no affect on [Ca 2ϩ ] i or cyclic nucleotides in any experiments. Thrombin and ADP (Sigma) were dissolved in deionized water; ionomycin (Sigma) was dissolved in DMSO; Isobutyl methylxanthine (Sigma) was dissolved in DMSO; and L-NMMA (Sigma) was dissolved in deionized water. Fura 2 acetoxymethyl ester (fura 2-AM) (Molecular Probes) was dissolved in DMSO.
Preparation of Platelets
Platelets were obtained from 37 healthy Japanese volunteers (14 men, 15 premenopausal women, and 8 postmenopausal women; mean ageϮSD, 38Ϯ16 years). None of the subjects had taken any medication for at least 2 weeks before the study. All gave their informed consent for participation in the study. The premenopausal women were within 1 week of onset of a menstrual period, a time of low levels of circulating plasma estradiol and progesterone. Their mean plasma concentration of 17␤-estradiol was 35.6Ϯ5.6 pg/mL, and progesterone was 0.46Ϯ0.06 ng/mL. In the postmenopausal women, the plasma concentration of 17␤-estradiol was 13.4Ϯ3.5 pg/mL. Plasma hormone levels were measured by use of an enzyme immunoassay kit (Boehringer Mannheim). Venous blood was drawn from each subject into 1/10 volume of 3.8% sodium citrate by use of the two-syringe technique. Blood samples were centrifuged at 800g for 5 minutes at room temperature to obtain platelet-rich plasma, which was gel filtered through a Sepharose 2B-CL column (Pharmacia LKB Biotechnology) that had been equilibrated with a medium that contained (in mmol/L) NaCl 145, KCl 5, MgSO 4 1, HEPES 10, and glucose 5 (pH 7.4).
Determination of Platelet Aggregation
For the aggregation studies, we used blood platelets from all 37 subjects at each concentration of the 17␤-estradiol pretreatment for each agonist. The number of platelets was adjusted to 10 8 /mL. CaCl 2 was added at a final concentration of 1 mmol/L. Gel-filtered platelets were used in the evaluation of thrombin stimulation. Platelet-poor plasma and plateletrich plasma were used for evaluating stimulation by ADP. 
Measurement of Cytosolic Concentration of Free Ca
2؉
For the measurement of [Ca 2ϩ ] i , the washed platelet solution was adjusted to a concentration of 10 8 cells/mL and incubated for 30 minutes at 37°C with fura 2-AM 2 mol/L together with 0.02% Pluronic F127 (Molecular Probes). The fura 2-loaded platelet suspension was incubated for 20 minutes at 37°C with 17␣-estradiol or 17␤-estradiol, each at a final concentration of 10 Ϫ8 to 10 Ϫ4 mol/L, or with ethanol. This step was followed by a 10-minute incubation with L-NMMA 1 mmol/L or vehicle. The platelet suspension was refiltered through the Sepharose column to remove the extracellular fura 2-AM. Next, the suspension was adjusted to a concentration of 10 7 platelets per mL, and CaCl 2 was added at a final concentration of 1 mmol/L. An aliquot of the cell suspension was stirred in a quartz cuvette at 37°C, and fluorescence was monitored with a spectrofluorophotometer (DM3000CM, SPEX Industries). The excitation wavelengths were 340 and 380 nm and the emission wavelength was 510 nm. [Ca 2ϩ ] i was calculated by use of the general formula described by Grynkiewicz 23 as follows: ] i , the Ca 2ϩ transient was measured at 5-second intervals for 30 seconds after the peak response to thrombin 1.0 U/mL in the absence of extracellular Ca 2ϩ . The slope of and the area under the plotted line were calculated to determine Ca 2ϩ extrusion and reuptake. Fluorescence was corrected for extracellular dye leakage with EGTA and for autofluorescence by subtracting the fluorescence of unloaded platelets.
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Assay of Cyclic Nucleotides and Determination of Intraplatelet cAMP and cGMP
Gel-filtered platelets, 10 8 /mL, were diluted with HEPES buffer that contained 1 mmol/L CaCl 2 . Platelets sampled from 12 subjects were preincubated for 20 minutes at 37°C with 17␣-estradiol, 17␤- estradiol, or ethanol, followed by a 5-minute incubation with 0.1 mmol/L isobutyl methylxanthine 26 ; then 1.0 U/mL thrombin was added. After 30 seconds, the samples were treated with ice-cold 25% perchloric acid to stop the reaction and stored at Ϫ80°C. After the samples had been thawed at 4°C, the concentrations of cAMP and cGMP were measured by use of an enzyme immunoassay kit with acetylation 27 (Amersham).
TABLE 2. Effect of 17␤-Estradiol on Platelet Aggregation
17␤-Estradiol Pretreatment ϩL-NMMA (1 mmol/L) and 10 Ϫ4 mol/L 17␤-Estradiol Control 10 Ϫ8 mol/L 10 Ϫ7 mol/L 10 Ϫ6 mol/L 10 Ϫ5 mol/L 10 Ϫ4 mol/L
NO (Nitrite/Nitrate) Analysis
Platelet counts were adjusted to 10 8 /mL by diluting the gel-filtered platelets with HEPES buffer. CaCl 2 was added at a final concentration of 1 mmol/L. The platelet samples were incubated for 20 minutes at 37°C with 17␣-estradiol, 17␤-estradiol, or ethanol, followed by a 10-minute incubation with 1 mmol/L L-NMMA or vehicle. The reaction was stopped by adding ice-cold 25% perchloric acid 30 seconds after thrombin (1.0 U/mL) had been added, and the samples were stored at Ϫ80°C. Platelet levels of NO were determined with a kit for assaying nitrite/nitrate (Cayman Chemical Co) by reacting each sample with Griess reagent. Absorbance was measured at 540 nm. 28 
Statistical Analysis
Values are expressed as meanϮSEM. Comparisons between groups were made by one-way ANOVA. Changes in each variable over time were compared among the three groups of subjects by use of a two-factor (group and time) repeated-measures ANOVA and were analyzed by Scheffé's F test. A level of PϽ0.05 was accepted as statistically significant.
Results
Concentration of 17␤-Estradiol in Platelets Preincubated With 17␤-Estradiol
We measured the concentration of 17␤-estradiol in platelets from 10 of the male subjects. The number of platelets was adjusted to 10 8 /mL, and they were then preincubated with 17␤-estradiol at a final concentration of 10 Ϫ8 to 10 Ϫ4 mol/L or with ethanol. The refiltered samples were treated with 25% perchloric acid and the concentration of 17␤-estradiol was measured. The results are shown in Table 1 . The plasma concentration of 17␤-estradiol in the male subjects was 17.5Ϯ3.6 pg/mL. We also measured the concentration of 17␤-estradiol in 6 premenopausal women whose plasma concentration of 17␤-estradiol was 105.9Ϯ16.8 pg/mL. The intraplatelet concentration of 17␤-estradiol in the 6 premenopausal women was 1352Ϯ205 pg/mL.
Effect of Estradiol on Platelet Aggregation
Concentrations of 17␤-estradiol of 10 Ϫ8 to 10 Ϫ6 mol/L had no effect on platelet aggregation. At concentrations Ͼ10 Ϫ5 mol/L, 17␤-estradiol dose-dependently reduced the platelet aggregation induced by thrombin as well as that by ADP according to the percent maximal aggregation and the area under the aggregation curve ( Table 2 ). The inhibitory effects of 17␤-estradiol on platelet aggregation were blunted by L-NMMA. The inhibitory effects of 17␤-estradiol on platelet aggregation were greater after ADP induction than after thrombin induction. At 10 Ϫ8 to 10 Ϫ4 mol/L, 17␣-estradiol had no effect on platelet aggregation (data not shown). 
Effect of 17␤-Estradiol on Platelet [Ca 2؉ ] i
Estrogen pretreatment had no effect on the intracellular concentration of fura 2, leakage of this dye, or R max , the index of hydrolysis of the fluorescence indicator. We investigated the metabolism of Ca 2ϩ in platelets that had been pretreated with 17␤-estradiol at concentration Ͼ10 Ϫ5 mol/L ( (Table 3) . However, the rate of decay of platelet [Ca 2ϩ ] i after the peak response to 1.0 U/mL thrombin in the absence of extracellular Ca 2ϩ was significantly accelerated (PϽ0.05, Figure 1) , and the area under the declining curve of [Ca 2ϩ ]i was decreased (PϽ0.05) by 17␤-estradiol (10 Ϫ5 to 10 Ϫ4 mol/L) in a concentration-dependent manner, although the peak [Ca 2ϩ ] i was unaffected. The effect of 17␤-estradiol on the rate of decay of platelet [Ca 2ϩ ] i was blunted by L-NMMA. Figure 2 shows the relationship between these variables among the three groups with respect to the area under the platelet aggregation curve and the area of accumulated [Ca 2ϩ ] i after the peak had been reached by stimulation with thrombin. A highly significant correlation was observed between these two areas (rϭ0.857, PϽ0.0001). Ϫ4 mol/L 17␤-estradiol. There was a highly significant correlation between these two areas (rϭ0.857, PϽ0.0001).
Effect of 17␤-Estradiol on cAMP and cGMP in Platelets
The effects of estrogen on the intracellular concentrations of cyclic nucleotides are shown in Figure 3 . Pretreatment of platelets with 17␤-estradiol or 17␣-estradiol at concentrations between 10 Ϫ8 and 10 Ϫ4 mol/L had no effect on the intracellular concentration of cAMP after stimulation by thrombin. The intracellular levels of cGMP in platelets stimulated by thrombin were increased by pretreatment with 17␤-estradiol at concentrationsϾ10
Ϫ5 mol/L (PϽ0.05, Figure 3 ) but were unaffected by pretreatment with 17␣-estradiol.
Effect of 17␤-Estradiol on NO in Platelets
The effects of estrogen on the NO content of platelets are shown in Figure 4 . The intracellular concentration of NO was increased by pretreating platelets with 17␤-estradiol at concentrations Ͼ10 Ϫ5 mol/L after stimulation by thrombin. This effect of 17␤-estradiol was blunted by L-NMMA. Pretreating the platelets with 17␣-estradiol did not alter the synthesis of NO. Figure 5 shows the relationship among these variables in the three groups with respect to the area of accumulated [Ca 2ϩ ] i after stimulation with thrombin and the level of NO synthesis. A highly significant correlation was observed between these two parameters (rϭ0.954, PϽ0.0001).
Discussion
The present study has demonstrated the ability of 17␤-estradiol to reduce platelet aggregation, which plays a key role in the formation of atherosclerotic plaque. The suppressive effect of estrogen on platelet activity may be one of the mechanisms responsible for its beneficial effects in reducing the incidence of cardiovascular events in postmenopausal women. We also investigated the mechanism of the antiplatelet effect of estrogen. Because [Ca 2ϩ ] i is one of the most important cellular second messengers that determine platelet function, we studied the effect of pretreatment with estradiol on Ca 2ϩ handling in platelets. 17␤-Estradiol did not alter baseline [Ca 2ϩ ] i , thrombin-or ADP-induced Ca 2ϩ influx, release of Ca 2ϩ from internal stores, or the size of internal Ca 2ϩ stores. Although 17␤-estradiol did not alter the peak amplitude of thrombin response in Ca 2ϩ -free medium, this steroid did potentiate return of the Ca 2ϩ transient to resting levels after stimulation by thrombin due to an increase in Ca 2ϩ reuptake or its extrusion. In addition, the area under the curve of platelet aggregation was strongly correlated with the area under the declining line of postpeak [Ca 2ϩ ] i rather than with peak [Ca 2ϩ ] i . A prolonged Ca 2ϩ response evokes a significant increase in the secretion of dense granules of platelets (degranulation 29 ); thus, an early Ca 2ϩ decay due to pretreatment with 17␤-estradiol would be expected to reduce such secretion. There is no conflict between the ability of 17␤-estradiol to reduce platelet aggregation and the acceleration of [Ca 2ϩ ] i recovery after the agonist-stimulated peak. Methodological issues are important in the assessment of Ca 2ϩ handling in fura 2-loaded cells. 25 We attempted to minimize the methodological problems that might have obscured the effects of estrogen. First, we demonstrated that estrogen pretreatment lacked an effect on the intracellular metabolism of fura 2, such as the intracellular concentration of fura 2 and R max , which is the index of dye ester hydrolysis. We were able to confidently compare [Ca 2ϩ ] i values determined in fura 2-loaded platelets from the different groups. Second, we corrected for fura 2 leakage, which, if uncorrected, leads to errors in calculating [Ca 2ϩ ] i . Third, to minimize cell activation, we separated the platelets by gel filtration instead of centrifugation. Basal [Ca 2ϩ ] i in the present study was low compared with previously reported results, due to differences in the method of determining [Ca 2ϩ ] i . Our estimate of basal [Ca 2ϩ ] i , however, was within the range of previously reported values from studies that used a similar method. 27, 30 It has been suggested that increased levels of cAMP and cGMP activate the resequestration of Ca 2ϩ into internal stores and the extrusion of Ca 2ϩ across the plasma membrane. [31] [32] [33] In a study of the effect of estrogen on the metabolism of arachidonic acid by aortas and platelets in rats, 17␤-estradiol was found to significantly stimulate the production of prostaglandin I 2 in the aorta but lacked a significant effect on thromboxane biosynthesis in platelets. 34 To clarify the relevance of the altered Ca 2ϩ handling caused by 17␤-estradiol and cyclic nucleotides, we measured the platelet levels of cAMP and cGMP. Pretreating the platelets with 17␤-estradiol had no effect on the levels of cAMP. Thus, the effect of 17␤-estradiol appeared not to be mediated by cAMP metabolism. The levels of cGMP, however, were increased by concentrations of 17␤-estradiol Ͼ10 Ϫ5 mol/L. The ability of estrogen to accelerate Ca 2ϩ decay may be mediated, at least in part, by an increase in intracellular cGMP.
Several cell types possess an L-arginine/NO pathway. Use of the reverse transcription-polymerase chain reaction has demonstrated expression of mRNA for the constitutive, endothelial form of NO synthase in human platelets. 35, 36 Gel electrophoresis identified a protein band of Ϸ130 kDa with NO synthase activity in the platelet cytosol. This direct evidence for the presence of a constitutive form of NO synthase is supported by other findings; the elevation of intraplatelet levels of cGMP by the NO-like compound S-nitrosocysteine has been correlated with the inhibition of human platelet secretion. 37 The effect of N G nitro-L-arginine methyl ester on platelet P-selectin expression, which is used as a marker of ␣-degranulation, has been shown to be mediated primarily by NO and cGMP. 38 Recent studies have confirmed a relationship between estrogen and NO. Several studies have shown that estrogen directly modifies the L-arginine/NO pathway in vascular endothelial cells. [39] [40] [41] Studies in vivo have found that estrogen potentiates endothelium-dependent vasodilation. 9, 10 Other studies have found that estrogen increases NO synthesis in human aortic endothelial cells. Because 17␤-estradiol is intimately linked to NO synthesis in endothelial cells and human platelets also have an intrinsic L-arginine/NO pathway, it is possible that 17␤-estradiol influences the intraplatelet synthesis of NO. We analyzed the nitrite/nitrate concentration in platelets and found that pretreatment with 17␤-estradiol increased the platelet concentration of nitrite/nitrate and that this effect was blunted by L-NMMA. These findings indicate that 17␤-estradiol increases cGMP via the stimulation of intrinsic NO synthesis in human platelets.
The effects of 17␤-estradiol on platelet aggregation and [Ca 2ϩ ] i decay were blunted by L-NMMA. We also observed a highly significant correlation between the area of accumulated [Ca 2ϩ ] i after stimulation by thrombin and the level of NO synthesis. This correlation suggests that the effect of 17␤-estradiol on human platelet aggregation is a consequence of interactions between NO synthesis, cyclic nucleotides, and [Ca 2ϩ ] i . The concentration of 17␤-estradiol at which effects were observed (10 Ϫ5 to Ϫ4 mol/L) was higher than its normal circulating levels (typically 10 Ϫ8 to 10 Ϫ10 mol/L). The fact that such supraphysiological levels of 17␤-estradiol were required for the inhibition of platelet function suggests several possibilities. Higher concentrations of hormones are required for some short-term membrane effects in vitro. There is a possibility that chronic exposure of circulating platelets to physiological levels of 17␤-estradiol in vivo may have the same effect as the supraphysiological levels of 17␤-estradiol in vitro. We measured the intraplatelet concentration of 17␤-estradiol (preincubation with 10 Ϫ8 to 10 Ϫ4 mol/L 17␤-estradiol) in men. The intraplatelet concentration of 17␤-estradiol in the male subjects did not reach physiological levels as in premenopausal women until the concentration of 17␤-estradiol for preincubation exceeded 10 Ϫ5 mol/L. The mechanism by which 17␤-estradiol is taken into platelets has not been clarified. Because there is a significant difference in the concentration of 17␤-estradiol between the inside and outside of platelets, we suggest that some transport mechanism exists in platelets and that 17␤-estradiol may partition into the platelet membrane pool. Therefore, in some acute events, such mechanisms may abruptly increase the concentration of 17␤-estradiol within platelets.
Estrogen receptors are present in the nucleus, where they stimulate the synthesis of mRNA and protein. 42 Given that platelets are anuclear and that the time course of estrogen action is very rapid, it is possible that a high concentration of this steroid exerts nonspecific effects on platelet membrane fluidity. However, because 17␣-estradiol did not affect platelet function, we suggest that the observed effects of 17␤-estradiol were specific to this hormone. Previous studies have shown that several kinds of cells in some mammalian species may bear nongenomic cell surface receptors for 17␤-estradiol. 43, 44 As a result, 17␤-estradiol may act on an as-yetunidentified platelet membrane receptor.
In conclusion, 17␤-estradiol appears to play an important role in inhibiting the aggregation of human platelets in vitro. The probable mechanism is the reduction of [Ca 2ϩ ] i by the increased production of cGMP that is dependent on NO.
